9 results about "Serious infection" patented technology

The purpose of the present invention is to provide a novel blood-brain barrier permeability regulator.　The present invention pertains to a blood-brain barrier permeability regulator containing a compound represented by formula (I) (Symbols in the formula (I) are as defined in the present specification.) or an isomer thereof, or a salt thereof. The present invention also pertains to a medicine for preventing and / or treating various brain diseases, severe infections, or sepsis by using the compound or an isomer thereof, or a salt thereof alone or in combination with a drug for preventing and / or treating a brain disease.

The application discloses application of PTN in preparation of products for treating cognitive impairment caused by severe infection. The inhibitor of PTN provided by the application can inhibit chronic neuroinflammation, thereby preventing and inhibiting formation and development of late cognitive impairment caused by severe infection, and meanwhile, inhibition of expression or function of PTN can effectively block damage of infiltrating macrophages to microglia cells, thereby providing a new direction for treatment of related diseases.

Subject matter of the present invention is an angiotensin-receptor-agonist and / or a precursor thereof for use in the treatment of a disease in a subject, • wherein said disease is selected from the group comprising heart failure, chronic heart failure, acute heart failure (AHF), myocardial infarction (MI), stroke, liver failure, burn injuries, traumatic injuries, severe infection (microbial, viral (e.g. AIDS), parasitic diseases (e.g. Malaria)), SIRS or sepsis, cancer, acute kidney injury (AKI), CNS disorders (e.g. seizures, neurodegenerative diseases), autoimmune diseases, vascular diseases, hypotension and shock, and • wherein said subject has an amount of DPP3 protein and / or DPP3 activity in a sample of bodily fluid that is above a predetermined threshold.

The present invention refers to an in vitro method for the prognosis of a Respiratory Syncytial Virus (RSV) infection, or for differentiating patients suffering from a severe RSV infection from patients who have a mild or moderate RSV.

The present invention describes methods for obtaining functionalized polymeric surfaces (MPn-PSm) from polymers or copolymers with appropriate functionalizations (X), which can be a halogen of a leaving group, such as polyvinyl chloride (MP1) and (chloromethyl) polystyrene-Merrifield (MP2), and curcumin photosensitizers (PS1), meso-tetra(aryl) porphyrins, chlorins or bacteriochlorins halogenated and functionalized with nucleophilic groups (PS2), in particular including P2 of the type meso-imidazoyl-porphyrins, chlorins or bacteriochlorins (PS3). The structures of all the photosensitizers in the present application incorporate a functional group (Y), which is a OH, SH or NH 2 nucleophile. The application also describes the covalent bonding process of the photosensitizers PS1-PS3 to the functional polymeric materials MP1-MP2 by means of a nucleophilic substitution reaction to prepare the MPn-Psm products. The formed products prevent microbial proliferation, which can cause the serious infections that are one of the main causes of death in patients using these devices.

Adverse outcomes of CAR-T such as hematotoxicity with prolonged cytopenia and infectious complications represent a challenging clinical problem after CAR-T therapy; however, current predictive models rely on blood counts and general inflammatory lab markers (ferritin, CRP) only and lack mechanistic / functional insights. Prolonged cytopenias after CAR-T are associated with endothelial alteration, characterized by reduced ANG1, E-selectin and MMP-1, and increased ANG2:ANG1 ratio, VCAM-1 and Thrombomodulin early after CAR-T. It was found that Patients with high baseline sIL-2R and VCAM-1 not only show more prolonged neutropenia and a more aplastic neutrophil recovery but also experience more severe infectious complications. High baseline VCAM-1 is associated with significantly worse peak CD8 CAR-T cell expansion and separates MM patients with worse overall response (Figure 5, Figure s5) Baseline sIL-2R and VCAM-1 have high predictive value for adverse outcomes, such as prolonged neutropenia, severe infections and death, and can further improve existing models.

Adverse outcomes of CAR-T such as hematotoxicity with prolonged cytopenia and infectious complications represent a challenging clinical problem after CAR-T therapy; however, current predictive models rely on blood counts and general inflammatory lab markers (ferritin, CRP) only and lack mechanistic / functional insights. Prolonged cytopenias after CAR-T are associated with endothelial alteration, characterized by reduced ANG1, E-selectin and MMP-1, and increased ANG2:ANG1 ratio, VCAM-1 and Thrombomodulin early after CAR-T. It was found that Patients with high baseline sIL-2R and VCAM-1 not only show more prolonged neutropenia and a more aplastic neutrophil recovery but also experience more severe infectious complications. High baseline VCAM-1 is associated with significantly worse peak CD8 CAR-T cell expansion and separates MM patients with worse overall response (Figure 5, Figure s5) Baseline sIL-2R and VCAM-1 have high predictive value for adverse outcomes, such as prolonged neutropenia, severe infections and death, and can further improve existing models.

This invention discloses a colorimetric card for early warning drainage fluid, comprising a card body, a colorimetric area, a central hollow area, an elastic fitting structure, a light-shielding structure, a time-recording structure, an independent detection piece, and sealed packaging. The card body has a colorimetric area and a central hollow area. The colorimetric area includes a normal zone, an infection warning zone, and a severe infection zone. The elastic fitting structure is located on the back of the card body, allowing the card body to conform to the curved surface of the drainage bag. The light-shielding structure is an extension of the card body, blocking external ambient light during colorimetric analysis. The time-recording structure includes a preset time node area and a blank supplement area, meeting the flexible monitoring needs of different drainage times in various departments. The independent detection piece is independent of the card body, with a pH detection element mounted on it, and is individually packaged in sealed packaging. This invention is applicable to drainage fluid monitoring in multiple clinical departments, including general surgery, hepatobiliary surgery, neurosurgery, urology, thoracic surgery, and obstetrics and gynecology. The colorimetric unit corresponds to CMYK values, RGB values, or Pantone color codes, allowing a color difference tolerance of ±5%. The beneficial effects of this invention are: direct observation of liquid color through the drainage bag; elastic fit structure design to fit the curved surface; light shielding structure to reduce ambient light interference; standardized color measurement to ensure batch consistency; flexible time recording to meet the needs of various departments; and independent pH detection strips for flexible and convenient testing.

The invention discloses application of PTN in preparation of a product for treating cognitive impairment caused by serious infection. The PTN inhibitor provided by the invention can inhibit chronic neuroinflammation so as to prevent and inhibit the formation and development of advanced cognitive impairment caused by serious infection, and meanwhile, the damage of infiltrating macrophages to microglial cells can be effectively blocked by inhibiting the expression or function of PTN, so that a new direction is provided for the treatment of related diseases.